Market Overview

Momenta Pharmaceuticals Falls 17% on Patent Infringement Ruling

Related MNTA
Momenta Pharmaceuticals Announces Acceptance Of A Clinical Trial Application In Europe for M923, A Biosimilar Version Of Humira
Stocks Hitting 52-Week Lows

Momenta Pharmaceuticals (NASDAQ: MNTA) is trading lower on the session after announcing that Teva Pharmaceutical (NASDAQ: TEVA) received a favorable ruling in COPAXONE patent infringement case. The decision is subject to appeal.

Craig Wheeler, President and Chief Executive Officer of Momenta. "We are disappointed that the court determined that Teva's patents were valid and infringed, and we look forward to reading the full opinion to understand its reasoning. We remain confident in our legal position and we intend to appeal."

Momenta Pharmaceuticals is currently trading at $14.02, a loss of $2.99 or 17.61%.

Posted-In: Intraday Update Movers

 

Related Articles (MNTA + TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters